Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of life sciences company Sequenom
So what: MultiPlan's clients will now have access to Sequenom's MaterniT21 PLUS test, used for pregnant women at increased risk for fetal aneuploidy, which should give Sequenom sales a much-needed boost. The shares have been beaten down over the past year on concerns over compromised data, but today's big endorsement could serve as a turning point in sentiment.
Now what: Don't let this pop keep you from looking into the stock. Even with the rally, Sequenom shares are still down about 45% from their June highs. When you couple that battered stock price with the company's cash-rich balance sheet and still-attractive growth prospects, Sequenom seems to have plenty of upside left.
Interested in more info on Sequenom? Add it to your watchlist.
